As I understand it, there are two distinct mechanisms which have been used to reduce the peripheral metabolism of levodopa:
- DDC inhibitor (e.g carbidopa). Carbidopa [1] "inhibits aromatic-L-amino-acid decarboxylase (DOPA decarboxylase or DDC), ... an enzyme important in the ... biosynthesis of L-DOPA to dopamine (DA). DDC exists both outside of (body periphery) and within the confines of the blood brain barrier."
- COMT inhibitor (e.g. entacapone). Entacapone [2] "is a selective and reversible inhibitor of the enzyme catechol-O-methyltransferase (COMT)... When taken together with levodopa (L-DOPA) and carbidopa, entacapone stops catechol-O-methyltransferase from breaking down and metabolizing levodopa, resulting in an overall increase of levodopa remaining in the brain and body."
So, there's Sinemet (= levodopa + carbidopa) and Stalevo (= levodopa + carbidopa + entacapone). But, I've never seen levodopa + entacapone (i.e. without carbidopa). Why is this?
References:
[1]
Carbidopa - Wikipedia
[2]
Entacapone - Wikipedia
John